Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 04 - 20 save search
Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer
Published: 2021-04-20 (Crawled : 13:15) - biospace.com/
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -3.24%
H: 1.24%
C: -0.41%
gene therapy therapy gene therapies
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Published: 2021-04-20 (Crawled : 13:00) - biospace.com/
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.05%
H: 0.52%
C: -11.92%
diabetes gene therapy therapy license gene therapies
Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy
Published: 2021-04-20 (Crawled : 13:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: 7.34%
H: 2.99%
C: -2.56%
immunotherapy therapy cancer license therapeutics
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform
Published: 2021-04-20 (Crawled : 13:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: 7.34%
H: 2.99%
C: -2.56%
immunotherapy therapy cancer license
Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
Published: 2021-04-20 (Crawled : 12:00) - biospace.com/
ITCI 1 d | $72.29 0.4% 0.4% 2.2M
|
Health Technology
|
| O: 0.17%
H: 2.25%
C: 1.26%
therapy
Israel's Kamada forges ahead with development of new anti-Covid immunoglobulin therapy in partnership with Kedrion Biopharma of Italy
Published: 2021-04-20 (Crawled : 11:00) - prnewswire.com
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: -1.63%
covid israel partnership biopharma anti-covid therapy
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
Published: 2021-04-20 (Crawled : 06:00) - biospace.com/
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.01%
H: 2.16%
C: 1.56%
disease alzheimer phase 2 therapy phase 2b research trial alzheimer’s alzheimer's disease alzheimer's lecanemab
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
Published: 2021-04-19 (Crawled : 00:00) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.01%
H: 2.16%
C: 1.56%
disease alzheimer phase 2 therapy phase 2b research trial alzheimer’s alzheimer's disease alzheimer's lecanemab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.